BioVaxys Technology Corp.

OTC: BVAXF · Healthcare · Biotechnology

Canadian filerHQ Etobicoke, BCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 29

v0.1 · 5/100 weight · pillars only

↑ market scale, disclosure history · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.9M

Employees

Market cap

$4.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2024

Net income-$2.9M-4.0M CAD2024

Operating income-$2.3M-3.1M CAD2024

Total assets$934.7k1.3M CAD2024

Liabilities$2.3M3.2M CAD2024

Equity-$1.4M-1.9M CAD2024

Revenue trend

FY2019 – FY2024 · USD

FY19

FY20

FY21

FY22

FY23

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

BioVaxys Technology Corp. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Cardiac Biotech Solutions Inc.——Curis, Inc.52D WEED, Inc.19D REMSleep Holdings, Inc.19D

Key facts

CEOJames Christopher Passin

SectorHealthcare

IndustryBiotechnology

HeadquartersEtobicoke, BC

ExchangeOTC: BVAXF

Employees3

IPO date2018-12-28

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.